Moberg Pharma AB (publ) (MOB.ST) has a MoatMap StockRank of 55/100 based on Quality (34/100), Value (45/100), and Momentum (62/100) factor scores. The current signal is HOLD. Moberg Pharma is a micro-cap pharmaceutical company with high binary product risk and no alignment to our CDMO or advanced packaging themes.
Moberg Pharma AB is a Swedish specialty pharmaceutical company focused on commercializing proprietary, topically administered treatments for nail fungus (onychomycosis). The company's competitive moat is anchored by its patented drug delivery technology, MOB-015, which has demonstrated superior efficacy in clinical trials. It operates as a niche pharmaceutical developer leveraging partner networks for global distribution.
| Price | $1.11 |
| Market Cap | $51M |
| P/E (Forward) | -50.50 |
| Price/Book | 0.52 |
| Return on Invested Capital | -3.6% |
| Debt/Equity | 1.87 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
Moberg Pharma AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Sweden).